标题
Novel immune targets for the treatment of triple-negative breast cancer
作者
关键词
-
出版物
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 25, Issue 10, Pages 815-834
出版商
Informa UK Limited
发表日期
2021-11-12
DOI
10.1080/14728222.2021.2006187
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Liquid biopsy enters the clinic — implementation issues and future challenges
- (2021) Michail Ignatiadis et al. Nature Reviews Clinical Oncology
- Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials
- (2021) Paolo Tarantino et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Current Perspectives: SARS-CoV-2 vaccines for cancer patients: a call to action
- (2021) Chiara Corti et al. EUROPEAN JOURNAL OF CANCER
- Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
- (2021) Eric P Winer et al. LANCET ONCOLOGY
- Phase I/Ib clinical trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination With Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors
- (2021) Giuseppe Curigliano et al. CLINICAL CANCER RESEARCH
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
- (2021) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic Cancer Vaccines Revamping: Technology Advancements and Pitfalls
- (2021) G. Antonarelli et al. ANNALS OF ONCOLOGY
- Managing side effects of immune checkpoint inhibitors in breast cancer
- (2021) Carmen Criscitiello et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Toll-Like Receptors: General Molecular and Structural Biology
- (2021) Payam Behzadi et al. Journal of Immunology Research
- ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
- (2021) A. Gennari et al. ANNALS OF ONCOLOGY
- Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development
- (2021) Paolo Tarantino et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Pembrolizumab plus chemotherapy as neoadjuvant treatment for high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
- (2020) P. Schmid et al. ANNALS OF ONCOLOGY
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- FDA Approval Summary: Atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1
- (2020) Preeti Narayan et al. CLINICAL CANCER RESEARCH
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
- (2020) Rita Nanda et al. JAMA Oncology
- Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
- (2020) T. Karn et al. ANNALS OF ONCOLOGY
- Preliminary safety and efficacy of GX-I7, a long-acting interleukin-7, in combination with pembrolizumab in patients with refractory or recurrent metastatic triple negative breast cancer (mTNBC): Dose escalation period of Phase Ib/II study (KEYNOTE-899).
- (2020) Joohyuk Sohn et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms.
- (2020) Jason J. Luke et al. JOURNAL OF CLINICAL ONCOLOGY
- Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
- (2020) Adi Diab et al. Cancer Discovery
- Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
- (2020) Jieqiong Liu et al. Journal for ImmunoTherapy of Cancer
- Tumor-infiltrating lymphocytes (TILs) in ER+/HER2− breast cancer
- (2020) C. Criscitiello et al. BREAST CANCER RESEARCH AND TREATMENT
- Cellular immunotherapy in breast cancer: the quest for aconsistent biomarkers
- (2020) Konstantinos Venetis et al. CANCER TREATMENT REVIEWS
- Molecular Aspects and Future Perspectives of Cytokine-Based Anti-cancer Immunotherapy
- (2020) Daria S. Chulpanova et al. Frontiers in Cell and Developmental Biology
- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)†
- (2020) F. Cardoso et al. ANNALS OF ONCOLOGY
- Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
- (2020) Elizabeth A Mittendorf et al. LANCET
- How current assay approval policies are leading to unintended imprecision medicine
- (2020) Roberto Salgado et al. LANCET ONCOLOGY
- Emerging CAR-T Cell Therapy for the Treatment of Triple Negative Breast Cancer
- (2020) Sundee Dees et al. MOLECULAR CANCER THERAPEUTICS
- ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models
- (2020) Amanda Hanson et al. PLoS One
- Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis
- (2020) U. Dafni et al. EUROPEAN JOURNAL OF CANCER
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
- (2020) Javier Cortes et al. LANCET
- Defining the immunogram of breast cancer: a focus on clinical trials
- (2019) Paolo Tarantino et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets
- (2019) Luca Cassetta et al. CANCER CELL
- A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer – clinical results and biomarker analysis of GeparNuevo study
- (2019) S Loibl et al. ANNALS OF ONCOLOGY
- Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial
- (2019) Elizabeth A. Mittendorf et al. CLINICAL CANCER RESEARCH
- Sex-based heterogeneity in response to lung cancer immunotherapy: a systematic review and meta-analysis
- (2019) Fabio Conforti et al. JNCI-Journal of the National Cancer Institute
- Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
- (2019) Filipe Martins et al. Nature Reviews Clinical Oncology
- Current Landscape of Immunotherapy in Breast Cancer
- (2019) Sylvia Adams et al. JAMA Oncology
- Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis
- (2019) Max D. Wellenstein et al. NATURE
- The evolving landscape of ‘next-generation’ immune checkpoint inhibitors: A review
- (2019) Luca Mazzarella et al. EUROPEAN JOURNAL OF CANCER
- Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
- (2019) H J Burstein et al. ANNALS OF ONCOLOGY
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Peter Schmid et al. LANCET ONCOLOGY
- What Is the Role of Interleukins in Breast Cancer Bone Metastases? A Systematic Review of Preclinical and Clinical Evidence
- (2019) Francesca Salamanna et al. Cancers
- Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies
- (2018) Xiaojie Yu et al. CANCER CELL
- Targeting the microenvironment in solid tumors
- (2018) Carmen Belli et al. CANCER TREATMENT REVIEWS
- Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer
- (2018) Neil H. Segal et al. CLINICAL CANCER RESEARCH
- Regulation of the Immune Response by the Aryl Hydrocarbon Receptor
- (2018) Cristina Gutiérrez-Vázquez et al. IMMUNITY
- Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial
- (2018) Sonia Pernas et al. LANCET ONCOLOGY
- Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis
- (2018) Peter Savas et al. NATURE MEDICINE
- Targeting adenosine for cancer immunotherapy
- (2018) Robert D. Leone et al. Journal for ImmunoTherapy of Cancer
- ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 +/- nivolumab (nivo) in patients (pts) with advanced cancers.
- (2018) Timothy Anthony Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.
- (2018) David S. Hong et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase Ib/II study of lacnotuzumab (MCS110) combined with spartalizumab (PDR001) in patients (pts) with advanced tumors.
- (2018) Aitana Calvo et al. JOURNAL OF CLINICAL ONCOLOGY
- A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models
- (2018) Stephen B. Willingham et al. Cancer Immunology Research
- TIM-3 expression in breast cancer
- (2018) Samantha Burugu et al. OncoImmunology
- Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
- (2018) Leisha A. Emens et al. JAMA Oncology
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cutting Edge: Anti–TIM-3 Treatment Exacerbates Pulmonary Inflammation and Fibrosis in Mice
- (2017) Takuma Isshiki et al. JOURNAL OF IMMUNOLOGY
- Tumour-associated macrophages as treatment targets in oncology
- (2017) Alberto Mantovani et al. Nature Reviews Clinical Oncology
- Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
- (2017) Norikazu Masuda et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects
- (2017) Laura F. Hutchins et al. Oncotarget
- Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
- (2017) Julia Tchou et al. Cancer Immunology Research
- Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis
- (2017) Rajeev K. Shrimali et al. Cancer Immunology Research
- Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
- (2017) Michael A. Cannarile et al. Journal for ImmunoTherapy of Cancer
- The genomic landscape of breast cancer and its interaction with host immunity
- (2016) Stephen Luen et al. BREAST
- Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses
- (2016) Arabella Young et al. CANCER CELL
- Rationale for anti-GITR cancer immunotherapy
- (2016) Deborah A. Knee et al. EUROPEAN JOURNAL OF CANCER
- Rationale for anti-OX40 cancer immunotherapy
- (2016) Sandrine Aspeslagh et al. EUROPEAN JOURNAL OF CANCER
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- Novel TGF-β inhibitors ready for prime time in onco-immunology
- (2016) Armand de Gramont et al. OncoImmunology
- Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade
- (2016) Nina Eissler et al. OncoImmunology
- Targeting CD73 in the tumor microenvironment with MEDI9447
- (2016) Carl M. Hay et al. OncoImmunology
- Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States
- (2015) Sarah S. Mougalian et al. CANCER
- TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity
- (2015) Claire Vanpouille-Box et al. CANCER RESEARCH
- Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment
- (2015) S. Scala CLINICAL CANCER RESEARCH
- CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice
- (2015) Yunching Chen et al. HEPATOLOGY
- TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients
- (2015) Joe-Marc Chauvin et al. JOURNAL OF CLINICAL INVESTIGATION
- TIGIT predominantly regulates the immune response via regulatory T cells
- (2015) Sema Kurtulus et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy
- (2014) Carola H. Ries et al. CANCER CELL
- LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses
- (2014) F. Xu et al. CANCER RESEARCH
- Cell-specific and context-dependent effects of GITR in cancer, autoimmunity, and infection
- (2014) Derek L. Clouthier et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
- (2014) Xiaozhou Fan et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- (2014) Patricia Cortazar et al. LANCET
- CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
- (2014) Yu-Hwa Huang et al. NATURE
- OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
- (2013) B. D. Curti et al. CANCER RESEARCH
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
- (2013) Rikke B. Holmgaard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
- (2013) C. Feig et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- Tim-3: An Activation Marker and Activation Limiter of Innate Immune Cells
- (2013) Gencheng Han et al. Frontiers in Immunology
- Combination strategies to enhance antitumor ADCC
- (2012) Holbrook E Kohrt et al. Immunotherapy
- Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
- (2012) Shigeki Chiba et al. NATURE IMMUNOLOGY
- Prognostic Significance of Tumor-Associated Macrophages in Solid Tumor: A Meta-Analysis of the Literature
- (2012) Qiong-wen Zhang et al. PLoS One
- Anti-TIM3 Antibody Promotes T Cell IFN- -Mediated Antitumor Immunity and Suppresses Established Tumors
- (2011) S. F. Ngiow et al. CANCER RESEARCH
- The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti-CTLA-4 Therapy
- (2011) T. Fu et al. CANCER RESEARCH
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- Phase III Multicenter Clinical Trial of the Sialyl-TN (STn)-Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer
- (2011) D. Miles et al. ONCOLOGIST
- Inhibitory Fc Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies
- (2011) F. Li et al. SCIENCE
- A Therapeutic OX40 Agonist Dynamically Alters Dendritic, Endothelial, and T Cell Subsets within the Established Tumor Microenvironment
- (2010) A. D. Pardee et al. CANCER RESEARCH
- T Cell/Transmembrane, Ig, and Mucin-3 Allelic Variants Differentially Recognize Phosphatidylserine and Mediate Phagocytosis of Apoptotic Cells
- (2010) Rosemarie H. DeKruyff et al. JOURNAL OF IMMUNOLOGY
- First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity
- (2010) Chrystelle Brignone et al. Journal of Translational Medicine
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fc-mOX40L Fusion Protein Produces Complete Remission and Enhanced Survival in 2 Murine Tumor Models
- (2009) Rebecca E. Sadun et al. JOURNAL OF IMMUNOTHERAPY
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
- (2008) Cornelia Liedtke et al. JOURNAL OF CLINICAL ONCOLOGY
- OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
- (2008) Silvia Piconese et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Chemokine receptor antagonists: overcoming developmental hurdles
- (2008) Richard Horuk NATURE REVIEWS DRUG DISCOVERY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started